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ABSTRACT Fifteen percent of the mutations causing familial hypertrophic cardiomyopathy are in the troponin T gene. Most
mutations are clustered between residues 79 and 179, a region known to bind to tropomyosin at the C-terminus near the
complex between the N- and C-termini. Nine mutations were introduced into a troponin T fragment, Gly-hcTnT70–170, that is
soluble, -helical, binds to tropomyosin, promotes the binding of tropomyosin to actin, and stabilizes an overlap complex of
N-terminal and C-terminal tropomyosin peptides. Mutations between residues 92 and 110 (Arg92Leu, Arg92Gln, Arg92Trp,
Arg94Leu, Ala104Val, and Phe110Ile) impair tropomyosin-dependent functions of troponin T. Except for Ala104Val, these
mutants bound less strongly to a tropomyosin affinity column and were less able to stabilize the TM overlap complex, effects
that were correlated with increased stability of the troponin T, measured using circular dichroism. All were less effective in
promoting the binding of tropomyosin to actin. Mutations within residues 92–110 may cause disease because of altered
interaction with tropomyosin at the overlap region, critical for cooperative actin binding and regulatory function. A model for
a five-chained coiled-coil for troponin T in the tropomyosin overlap complex is presented. Mutations outside the region
(Ile79Asn, 160Glu, and Glu163Lys) functioned normally and must cause disease by another mechanism.
INTRODUCTION
Mutations in genes encoding sarcomeric proteins cause famil-
ial hypertrophic cardiomyopathy (FHC), an autosomal domi-
nant trait characterized by ventricular hypertrophy and myo-
cyte disarray which is often associated with sudden, premature
cardiac death. The gene encoding cardiac troponin T (TnT) is
one of the more frequently affected ones, accounting for
15% of documented FHC-causing mutations (Thierfelder et
al., 1994; Hernandez et al., 2001). The hcTnT mutations are
mostly characterized by a very mild and many times undetect-
able hypertrophy. However, the rate of sudden cardiac death is
often severe (Watkins et al., 1995).
Troponin T is a regulatory protein found in striated mus-
cles that forms a complex with troponin I (TnI) and troponin
C (TnC) that, together with tropomyosin (TM), is required
for Ca2-dependent regulation of muscle contraction (re-
viewed in Perry, 1998; Gordon et al., 2000). Troponin T
binds to both TnI and TnC in the Tn complex as well as to
TM, and possibly actin, on the thin filament (reviewed in
Perry, 1998; Gordon et al., 2000). The elongated shape of
the Tn complex (Flicker et al., 1982) and its position span-
ning the C-terminal third or more of TM (White et al., 1987;
Cabral-Lilly et al., 1997) is because of TnT (Fig. 1). The
elongated N-terminal end of TnT is oriented toward the
C-terminus of TM, including the head-to-tail overlap region
(Pato et al., 1981; Brisson et al., 1986). The C-terminal half
of TnT binds to TnI, to TnC and to the middle of TM in a
Ca2-sensitive manner (Pearlstone and Smillie, 1983; Bris-
son et al., 1986; Pan et al., 1991).
Studies of TnT fragments have identified the critical
region of the N-terminal domain. Fragments corresponding
to residues80–180 for cardiac, and residues50–150 for
skeletal muscle TnT, are highly -helical, bind to TM, and
increase the affinity of TM for actin (Jackson et al., 1975;
Pearlstone and Smillie, 1977; Hill et al., 1992; Hinkle et al.,
1999). Nine of the twelve loci of FHC-causing mutations
are located in this region, the remaining three being close to
the C-terminus (Fig. 1).
Despite the intensive research on FHC-causing mutations
of TnT, the disease mechanism(s) is (are) poorly under-
stood. Model systems have been developed to study the
disease ranging from analysis of purified proteins to study
of cardiac function in transgenic animals (reviewed in Her-
nandez et al., 2001). The model systems used to study the
disease are complex, and sometimes the same mutation
causes opposite effects in different models. For example,
R92Q-TnT exchanged into skinned rabbit cardiac muscle
fibers required lower levels of free Ca2 for tension gener-
ation (Morimoto et al., 1998), whereas adenovirus carrying
the same TnT mutant transfected into cultured rat or quail
cardiac myocytes required a higher calcium concentration
for tension generation (Sweeney et al., 1998; Rust et al.,
1999). Similar discrepancies have been reported for other
TnT mutations (Mukherjea et al., 1999; Tobacman et al.,
1999; Redwood et al., 2000). Clearly, in a structure as
complex as the myofibril there will be multiple disease
mechanisms, and the deficiencies of a single mutation will
be manifested at more than one level of contractile protein
function.
Because of the difficulties of working with complex
biological systems, we designed a model system to study the
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effect of individual mutations on TnT function as well as its
structure and stability. A fragment with residues 70–170 of
human cardiac TnT, expressed in Escherichia coli, is solu-
ble, binds to TM, promotes the binding of TM to actin, and
stabilizes a complex with N- and C-terminal TM model
peptides. Nine disease-causing mutations in this region
were individually introduced into the fragment. Mutations
in the residue 92–110 region altered the TM-dependent
functions of this TnT fragment whereas those outside the
region were neutral. We propose a model for the binding of
TnT to the C-terminus of TM at the N- to C-terminal
overlap region to explain the importance of the mutated
residues for TnT function.
MATERIALS AND METHODS
DNA constructs
The cDNA for Gly-hcTnT70–170 was prepared from pSBET (Schenk et al.,
1995) carrying an insert encoding full-length wild-type (wt) human cardiac
(hc) TnT (Thierfelder et al., 1994; Mukherjea et al., 1999). Using Pfu
Turbo DNA polymerase (Stratagene, La Jolla, CA) and the polymerase
chain reaction (PCR) protocol provided by the supplier, with oligonucle-
otides A and B (see Table 1) we inserted an N-terminal His6 purification
tag into full-length wt-hcTnT to create His6-hcTnT in pSBET. The oligo-
nucleotides also introduced a recognition site for tobacco etch virus (TEV)
protease to allow removal of the His6-tag after affinity purification, leaving
an N-terminal glycine with the recombinant protein (Gly-hcTnT). The
second mutagenesis step used the oligonucleotides C and D (Table 1) to
insert a stop-codon following codon 170 and a BamHI restriction site for
cloning, creating His6-hcTnT1–170. In this step circular pSBET with full-
length His6-hcTnT was used as a template. Oligonucleotides B and D were
5-phosphorylated to allow blunt end ligation of the purified PCR products.
To remove the codons for the amino acids 1–69 from the cDNA, a
recombinant PCR protocol was used (Higuchi, 1990). In two primary PCRs
the oligonucleotide sets E, F and G, H (Table 1) were used to amplify
fragments between the codon for Phe-70 and the T7-terminator, and
between the T7-promotor and the last codon (Gly) of the His6-tag, respec-
tively, to create His6-hcTnT70–170. As a template for the primary PCRs we
linearized His6-hcTnT1–170 in pSBET with BglII and EcoRI. In a secondary
PCR, the overlapping primary PCR products annealed, and recessed 3
ends were extended. Using only the outside primers from the above
mentioned oligonucleotide sets, His6- hcTnT70–170 was amplified between
the T7-promotor and T7-terminator. The PCR product was digested with
NdeI and BamHI and cloned into pSBET at these sites.
The same recombinant PCR protocol was used to introduce FHCmutations
into His6-hcTnT70–170. To facilitate the selection of mutant clones, oligonu-
cleotide primers were designed to contain a silent restriction site (see Table 1).
The correct cDNA sequences were confirmed by automated sequencing at the
University of Medicine and Dentistry of New Jersey DNA Core Facility,
Robert Wood Johnson Medical School, Piscataway, NJ.
Expression and purification of hcTnT peptides
His6-hcTnT70–170 was expressed in E. coli BL21(DE3) pLysS (Studier et
al., 1990). One-liter cultures in LB medium at OD590  0.6 were induced
with 0.4 mM isopropyl--D-thiogalactopyranoside and grown for 4 h. The
cells were collected by centrifugation and were lysed by adding 2 vol (v/w)
of 9 M urea, 750 mM NaCl, 30 mM imidazole, 7.5 mM 2-mercaptoethanol,
15% glycerol, 30 mM Tris, pH 8.0. The lysate was sonicated and the
cellular debris was removed by centrifugation at 22,000 rpm, 4°C, for 20
min in a Sorvall RC26Plus centrifuge equipped with a SLA-300 rotor.
His6-hcTnT70–170 was separated from bacterial proteins in the supernatant
by affinity chromatography on Ni-NTA agarose (Qiagen, Valencia, CA)
equilibrated with 6 M urea, 500 mM NaCl, 20 mM imidazole, 5 mM
2-mercaptoethanol, 10% glycerol, 20 mM Tris, pH 8.0. Bound His6-
hcTnT70–170 was eluted with 6 M urea, 100 mM NaCl, 100 mM imidazole,
5 mM 2-mercaptoethanol, 10% glycerol, 20 mM Tris, pH 8.0. Following
dialysis into 1 mM dithiothreitol (DTT), 1 mM NaN3, 0.5 mM EDTA, 50
mM Tris, pH 8.0, the His-tag was cleaved for 24 h at 30°C using 10 U of
His6-TEV protease per mg of peptide, leaving the C-terminal Gly of the tag
as the N-terminal residue of the hcTnT fragment (Gly-hcTnT70–170). Fol-
FIGURE 1 (A) Model of the troponin-tropomyosin complex (modified from Heeley et al., 1987). Only the first and the last180 residues of tropomyosin
are shown. (B) Schematic representation of human cardiac TnT structure with sites of FHC causing mutations (modified from Bonne et al., 1998). Arrows
indicate the different binding domains. References for FHC mutations are I79N, R92Q, and  Exon15,16 (Thierfelder et al., 1994); R92L (Forissier et al.,
1996); R92W (Moolman et al., 1997); R94C (D’Cruz et al., 2000); R94L (Varnava et al., 1999); A104V (Nakajima-Taniguchi et al., 1997); F110I, E160,
E163K, E244D, and R278C (Watkins et al., 1995); R130C and E163R (Koga et al., 1996); and S179F (Ho et al., 2000).
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lowing dialysis into 50 mM NaCl, 10 mM imidazole, pH 7.0, the His-tag
and protease were removed on a Ni-NTA agarose column. The yield was
20 mg/L of culture. The purity of the product was verified by SDS gel
electrophoresis and reverse-phase high-performance liquid chromatogra-
phy (HPLC). The mass was confirmed using electrospray mass spectros-
copy with a peak at 12576.0 Da (expected mass: 12574.9 Da).
Tropomyosin binding
Chicken -TM was ligated to cyanogen-bromide-activated Sepharose
(Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s protocol.
TnT peptides were bound to TM-Sepharose and eluted with a gradient from
50–750 mM NaCl in 1 mM EGTA, 1 mM NaN3, 10 mM imidazole, pH
6.5, at a flow rate of 0.5 ml/min. The protein concentration of each fraction
was determined by the Bradford method (Pande and Murthy, 1994) and by
densitometry of SDS-polyacrylamide gels using a Molecular Dynamics
300A computing densitometer (Molecular Dynamics, Sunnyvale, CA). The
NaCl concentration in each fraction was determined by measuring the
conductivity using a Radiometer Copenhagen model CDM3 conductivity
meter and comparing it with the conductivity of NaCl standards.
Tropomyosin binding to F-actin
The effect of the Gly-hcTnT70–170 fragments on the affinity of TM for actin
was measured by co-sedimentation. Chicken pectoral muscle -TM was
combined with the TnT peptides in a 1:1.2 molar ratio in 300 mMNaCl, 4 mM
MgCl2, 0.5 mM DTT, 10 mM 4-morpholineethanesulfonic acid (MES), pH
6.0, and centrifuged at 60,000 rpm, 20°C, for 25 min in a Beckman TLA-100
rotor to remove insoluble material. F-actin (5 M final concentration) was
combined with TM-TnT (0–6 M final concentration) in the same buffer and
centrifuged as before. The actin and TM were quantitated in SDS-polyacryl-
amide gels of the pellets using a Molecular Dynamics densitometer. The data
were fit to the Hill equation to determine the affinity of TM for actin
(SigmaPlot 5.0, Jandel Scientific, San Rafael, CA):
  nTMH/		1/Kapp
H TMH
, (1)
where [TM] is the total concentration of tropomyosin in the sample,  is the
observed TM/actin density ratio at [TM], n is the maximal TM/actin
density ratio, Kapp is the apparent association constant of TM for actin, and
H is the Hill coefficient.
Tropomyosin peptides
Synthetic N-terminal and C-terminal peptides of tropomyosin were com-
mercially synthesized, purified to 95% purity by reverse-phase HPLC
and analyzed by mass spectroscopy (SynPep, Dublin, CA). The N-terminal
peptide, AcTM1aZip, consisted of the first 14 residues of rat -TM and the
last 18 residues of the GCN4 leucine zipper and was N-acetylated (Green-
field et al., 1998). The peptide is a dimer in solution, and given concen-
trations are dimer concentrations. The C-terminal peptide, TM9a36ox,
consisted of the last 35 residues of rat -TM (SWISS-PROT database
accession number P04692) and an N-terminal cysteine. The N-terminal
cysteines were air-oxidized to form a coiled-coil dimer of the peptide.
Cross-linked peptide was separated from monomer by reverse phase
HPLC.
Circular dichroism studies
Circular dichroism (CD) data were collected on an Aviv model 62D
spectropolarimeter (Aviv, Lakewood, NJ) equipped with a five-sample
thermal equilibration chamber as previously described (Greenfield and
Hitchcock-DeGregori, 1995). TnT peptides were measured either alone or
in mixtures with N- and C-terminal TM model peptides. The stoichiometry
of Gly-hcTnT70–170 binding to the AcTM1aZip-TM9a36ox complex (the
overlap model) was determined by titrating an equimolar mixture of
AcTM1aZip and TM9a36ox with the TnT-peptide and monitoring the
effect on helical content at 222 nm.
Data were collected at a concentration of 17.5 M for each peptide in
10 mM potassium phosphate, pH 6.5, and 10 M for each peptide in 150
mM KCl, 10 mM potassium phosphate, pH 6.5, respectively. CD spectra
were measured at 0°C, and the -helical content of the TnT peptides was
TABLE 1 Oligonucleotide primers used to prepare Gly-hcTnT70-170 and to introduce FHC mutations
Primer Primer sequence Mutation Coding primer sequence*
Restriction
site
A 5-CATATGTCGTACTACCATCACCATCACC-
ATCACGATTACGATATCCCAACGACCGAA-
AACCTGTATTTTCAGGGCATGTCTGACATA-
GAAGAGGTGGTGG-3
I79N 5-CCCAACTTGGTACCTCCCAAGAACCCCGATGGAGAG-
3
KpnI
B 5-P-TATATCTCCTTCTTAAAGTTAAACAAA-
ATTATTTC-3
R92Q 5-GACTTTGATGATATCCACCAGAAGCGCATGGAG-3 EcoRV
C 5-TAATAGGATCCATGCATTTTGGGGGTTA-
CATCCAG-3
R92W 5-GACTTTGATGATATCCACTGGAAGCGCATGGAG-3 EcoRV
D 5-P-ATCCTCAGCCTTCCTCCTGTTCTCC-3 R92L 5-GACTTTGATGATATCCACTGGAAGCGCATGGAG-3 EcoRV
E 5-CCAACGACCGAAAACCTGTATTTTCAGGGC-
TTCATGCCCAACTTGGTGCCTCCCAAGATC-3
R92L 5-GACTTTGATGATATCCACCTGAAGCGCATGGAG-3 HindIII
F 5-GCTAGTTATTGCTCAGCGGTGGCAG-3 A104V 5-CATCCACCGGAAGCTTATGGAGAAGGACCTG-3 PstI
G 5-CGATCCCGCGAAATTAATACGACTCAC-3 F110I 5-GACCTGAATGAGCTGCAGGCGCTGATCGAGGCTCAC-
ATTGAGAACAGG-3
PstI
H 5-GATCTTGGGAGGCACCAAGTTGGGCATGAA-
GCCCTGAAAATACAGGTTTTCGGTCGTTGG-3
E160 5-GCTGAAGAGAGAGCTCGACGA GAGGAGGAGAACA-
GGAGGAAG-3
SacI
E163K 5-GCTGAAGAGAGAGCTCGACGAGAGGAGGAGAAGAA-
CAGGAGG-3
SacI
*Only the coding primer is shown in this table. These primers were used together with primer F in one primary PCR reaction. The reverse complements
of these primers were used together with primer G in the second primary PCR. FHC mutations are underlined, mutations that introduce a silent restriction
site are in italics.
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calculated from ellipticity data using the neural network program, CDNN
(Bo¨hm et al., 1992). Thermal stability measurements were performed by
following the ellipticity at 222 nm as a function of temperature between
0°C and 70°C. The midpoints of the thermal transitions (Tm) were deter-
mined from the first derivative of the melting curves.
General methods
Thin filament proteins were purified from chicken pectoral muscle using
previously published methods. Skeletal actin was prepared from acetone
powder (Hitchcock-DeGregori et al., 1982). -Tropomyosin was purified
from the isoelectric precipitate from a troponin preparation (Hitchcock-
DeGregori et al., 1985). SDS-polyacrylamide gel electrophoresis was per-
formed as described by Laemmli (1970). Unless mentioned otherwise, the
concentration of proteins and peptides was determined with the micro-
biuret method (Goa, 1953).
RESULTS
Design and purification of Gly-hcTnT70–170
We have developed a model system to test the effects of
FHC-causing mutations in TnT on interactions with TM and
actin, the two major targets of TnT. Because most of the
mutations are localized within a 100-residue region of TnT
(Fig. 1), we defined a fragment of TnT spanning this region
that retains the desired biological functions and is suitable
for structural studies. Reasons for taking this approach are
that TnT fragments are soluble, whereas full-length TnT is
poorly soluble, and our disenchanting experience where
similar studies using full-length TnT mutants gave conflict-
ing results (Mukherjea et al., 1999; Tobacman et al., 1999;
Redwood et al., 2000).
Previous studies of TnT fragments have been instrumen-
tal in specifying the functional domains of TnT. The design
of the fragment for use in the present investigation was
guided by the early work. Smillie and his co-workers
showed that skeletal TnT71–151, which corresponds to resi-
dues 101–181 in hcTnT, was 80% -helical and bound to
the N- and C-termini of TM (Pearlstone and Smillie, 1977;
Pato et al., 1981). This fragment includes the region that is
important for TnT to promote binding of TM to actin (Hill
et al., 1992; Hinkle et al., 1999).
We elected to use a fragment spanning residues 70–170
of hcTnT that includes most of the region originally shown
to bind well to TM (Jackson et al., 1975; Pearlstone and
Smillie, 1977), extended toward the N-terminus to include
eight of the nine sites of the FHC mutations in this region of
TnT (see Fig. 1; the S179F mutation had not been reported
at the time we designed the fragment (Ho et al., 2000)). The
hcTnT cDNA was modified to express hcTnT70–170 in E.
coli, in a form that leaves an N-terminal Gly following
enzymatic removal of a His6-tag used for affinity purifica-
tion (called Gly-hcTnT70–170; see Materials and Methods,
the Gly replaces a Ser at residue 69 in hcTnT). Functional
analysis of Gly-hcTnT70–170 showed that the fragment has
the desired properties: it is soluble, -helical, binds to TM,
stabilizes the head-to-tail overlap region of TM, and pro-
motes TM binding to actin. Its properties are similar to those
of a longer fragment we expressed, hcTnT58–181. We de-
signed the shorter peptide for its potential advantage in
structural studies and individually introduced the nine best-
documented FHC-causing mutations into the Gly-
hcTnT70–170 construct (see Materials and Methods).
Tropomyosin binding
Binding of the Gly-hcTnT70–170 fragments to TM-Sepha-
rose was measured by affinity chromatography, using the
ionic strength for elution as an estimate of relative affinity
for -tropomyosin (Table 2). Fig. 2 shows typical elution
profiles of R92W-Gly-hcTnT70–170 and the wild-type frag-
ment. Mutations that reduced TM affinity, in that they
eluted at about half the ionic strength of wild type, were
clustered between residues 92 and 110. Within this region,
only R92Q and A104V, both relatively conservative
changes, had no effect on TM binding. Mutations outside
this region (I79N, E160, and E163K) were neutral.
Promotion of tropomyosin binding to actin by
Gly-hcTnT70–170
Wild-type Gly-hcTnT70–170 promoted the binding of TM to
actin, increasing the affinity approximately threefold, mea-
sured by co-sedimentation (Fig. 3 A, Table 2). All six
mutations between residues 92 and 110 decreased the ability
of Gly-hcTnT70–170 to promote TM binding to actin (F110I
and A104V are shown in Fig. 3, B and C, respectively;
TABLE 2 TnT binding to TM and promotion of TM binding
to actin
Mutation
Elution from
TM column*
([NaCl] in mM)
Kapp of TM
for actin†
(105 M1)
No TnT – 2.00.1
wt 26016 6.60.4
I79N 283 6.7
R92L 146 5.2
R92Q 245 5.6
R92W 126 4.6
R94L 161 5.5
A104V 273 5.3
F110I 139 3.8
E160 275 6.4
E163K 273 5.9
*Determined at 1 mM EGTA, 1 mM NaN3, 10 mM imidazole, pH 6.5.
Values are the average of two to three measurements. Wild type was
measured seven times, and a standard deviation is given. Reproducibility of
mutants was within 30 mM.
†Data collected at 300 mM NaCl, 4 mM MgCl2, 0.5 mM DTT, 10 mM
MES, pH 6.0, 20°C, were fit to the Hill equation. Standard errors of curve
fitting to pooled data are 0.1  105 M1. Measurements were repeated
2–3 times except for no TnT and wt (6–10 times) shown with standard
deviations.
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Table 2). In contrast, mutations outside this region had little
effect. The ability of TnT to increase the affinity of TM for
actin seems to depend primarily on binding to TM. The
A104V mutation that showed normal TM-binding, how-
ever, may directly affect TM-actin interaction.
Secondary structure and conformational stability
Circular dichroism was used to determine the secondary
structure and thermal stability of wild-type and mutant
Gly-hcTnT70–170. The thermal denaturation of the TnT frag-
ment and both TM peptides was fully reversible. None of
the mutations affected the -helical content of Gly-
hcTnT70–170 (90  5% at 0°C, Table 3), but the thermal
stability of the -helix was altered by several mutations.
The thermal stability of Gly-hcTnT70–170 was concentration
dependent, suggesting that the fragment forms homodimers
or higher-order assemblies in solution. Therefore, all data
were collected at the same concentration. Fig. 4 A shows the
temperature dependence of the ellipticity at 222 nm, a
measure of -helix, of wt-Gly-hcTnT70–170 and two mu-
tants, A104V and F110I. The Tm values of the transitions
are shown in Table 3. The thermal transitions of the mutants
R92L, R92W, R94L, and F110I could not be fit to a single
transition model. Although there was a minor transition
with the Tm of the wild-type peptide, the major transition
occurred with a much higher Tm, suggesting that these
mutations stabilize the -helix and/or the formation of ho-
modimers. The most stable mutants are those that bind to
tropomyosin with reduced affinity and are impaired in pro-
moting TM binding to actin. A104V unfolded with a lower
Tm than wild type; it binds to TM with normal affinity
(Table 2). The effect of the other mutations on -helical
stability was minimal.
Stabilization of the N- to C-terminal tropomyosin
overlap complex by Gly-hcTnT70–170
Tropomyosin molecules associate head-to-tail along the ac-
tin filament and are proposed to overlap at their ends by
about eight to nine amino acids (McLachlan and Stewart,
FIGURE 2 Binding of Gly-hcTnT70–170 to tropomyosin-Sepharose.
Typical elution profiles of wild-type (——) and R92W-Gly-hcTnT70–170
(— — —). The straight line represents the NaCl concentration of the
gradient. Conditions: 50–750 mM NaCl, 1 mM EGTA, 1 mM NaN3, 10
mM imidazole, pH 6.5
FIGURE 3 Tropomyosin binding to actin filaments. TM binding is the
TM:actin ratio observed in densitometric analysis of Coomassie-Blue-
stained SDS gels of the actin-containing pellets following centrifugation.
The ratio observed at saturation reflects stoichiometric TM binding (TM:
actin 1:7). (A) In the presence (E) and absence () of wt-Gly-hcTnT70–170;
(B) In the presence of F110I; (C) In the presence of A104V. The dotted line
in B and C represents TM binding to actin in the presence of wt-Gly-
hcTnT70–170 taken from A. Error bars reflect the standard deviation of 3–10
independent measurements. Conditions: 300 mM NaCl, 4 mM MgCl2, 0.5
mM DTT, 10 mM MES, pH 6.0, 20°C.
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1975). Troponin promotes head-to-tail interaction, as mea-
sured using viscosity (Jackson et al., 1975) and increases the
length of the cooperative unit of TM along the actin fila-
ment (Geeves and Lehrer, 1994).
To measure the influence of FHC mutations on the inter-
action of Gly-hcTnT70–170 with the TM head-to-tail overlap
region, we developed a model system employing two syn-
thetic TM peptides. The N-terminal peptide, AcTM1aZip,
consists of the first 14 residues of rat striated muscle -TM
(encoded by exon 1a) and the last 18 residues of the GCN4
leucine zipper. We previously solved the structure of
AcTM1aZip using two-dimensional NMR (Greenfield et
al., 1998). The C-terminal peptide, TM9a36ox, consists of
the last 35 residues of rat striated muscle -TM (encoded by
exon 9a) and was cross-linked through an N-terminal cys-
teine. The mixture of the two peptides showed an increased
thermal stability (5.4°C) when compared with the sum of
the individual components, indicating the formation of a
complex. Although Gly-hcTnT70–170 bound weakly to the
C-terminal TM9a36ox (1.6°C), the binding was slightly
stronger than to the N-terminal AcTM1aZip (0.9°C).
However, it formed a stable ternary complex with the TM
overlap peptides, increasing the Tm by 7.6°C (Fig. 4 B).
When the TM overlap complex was titrated with increasing
concentrations of Gly-hcTnT70–170, the increase in elliptic-
ity saturated at a stoichiometry of one TnT to one overlap
complex (mol/mol) showing that the monomeric form of
Gly-hcTnT70–170 binds to TM.
The specificity of the peptide model of the TM overlap
was validated in a similar binding study using two other
synthetic peptides: TM9a39 (C-terminal 39 residues, en-
coded by rat exon 9a, specific to striated muscle TMs;
similar to TM9a36ox, but 39 residues long and not cross-
linked at the N-terminus) and TM9d39 (the corresponding
C-terminal 39 residues encoded by rat exon 9d, expressed in
smooth muscle and many nonmuscle TMs). Whereas
TM9a39 formed a stable complex with AcTM1aZip and
Gly-hcTnT70–170, Gly-hcTnT70–170 did not bind to TM9d39
or form a complex with TM9d39-AcTM1aZip (data not
shown). This observation is supported by earlier work
showing that the sequence encoded by exon 9a is required
for TM to bind to TnT (Pearlstone and Smillie, 1982;
Hammell and Hitchcock-DeGregori, 1996).
Most FHC mutations between residues 92 and 110 im-
paired the ability of Gly-hcTnT70–170 to stabilize the TM
head-to-tail overlap complex. The R92W and F110I muta-
tions were most detrimental (see Fig. 4 C and Table 3). The
stabilization by R92L, R92Q, and R94L was lower than that
of the wild type whereas I79N, E160, and E163K were
unaffected. The stabilization of the overlap complex by
A104V-Gly-hcTnT70-170 was slightly greater than with wild
type. This is probably due to a stabilizing effect of the TM
overlap complex on the A104V fragment, which by itself is
less stable than the wild-type TnT fragment.
In the CD experiments, the ability of Gly-hcTnT70–170 to
stabilize the TM overlap complex correlates with the effect
of the mutations on the Tm of the TnT fragment: the higher
the Tm, the less stabilization of the complex (Fig. 5). We
were concerned that this relationship might be trivial be-
cause the calculated increase in stability is based on the
difference between the Tm values of the sum of component
melting curves and the melting curve of the mixture. How-
ever, the binding to the TM affinity column and the Kapp of
TM for actin in the presence of Gly-hcTnT70–170 show the
TABLE 3 Properties of wild-type and FHC mutant Gly-hcTnT70-170 peptides and their complexes with AcTM1aZip and TM9a36ox
Peptide % -Helical content* Tm peptide
† (°C) Tm ternary complex
† (°C) Increase in stability‡ (°C)
wt-Gly-hcTnT70-170 90 33.5 36.1 7.6
I79N-Gly-hcTnT70-170 90 32.9 35.9 7.6
R92L-Gly-hcTnT70-170 93 32.8,44.4 35.1 4.1
R92Q-Gly-hcTnT70-170 87 36.0 34.8 4.8
R92W-Gly-hcTnT70-170 94 33.4,47.9 36.0 0.3
R94L-Gly-hcTnT70-170 91 31.8,44.2 35.6 3.0
A104V-Gly-hcTnT70-170 90 27.6 34.6 9.6
F110I-Gly-hcTnT70-170 90 32.6,50.9 34.5 2.3
E160-Gly-hcTnT70-170 93 34.1 36.6 7.0
E163K-Gly-hcTnT70-170 93 35.8 37.2 8.0
AcTM1aZip 85 22.7
TM9a36ox 57 17.0
AcTM1aZip  TM9a36ox 24.9§ 5.4§
wt-Gly-hcTnT70-170  AcTM1aZip 29.4
§ 0.9§
wt-Gly-hcTnT70-170  TM9a36ox 31.3
§ 1.6§
Data were collected at a peptide concentration of 17.5 M in 10 mM potassium phosphate, pH 6.5.
*Determined with neural network software CDNN (Bo¨hm et al., 1992); accuracy of method, 5%.
†Determined from the first derivative of the melting curve. Experiments with wt-Gly-hcTnT70-170 and the TM peptides were repeated at least three times
and showed that the reproducibility of Tm was usually better than 1°C.
‡The increase in stability is the difference between the Tm of the ternary complex and the Tm of the sum of Gly-hcTnT70-170 and the binary complex of
AcTM1aZip and TM9a36ox melting curves.
§Binary complex.
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same correlation with Tm (Fig. 5). The exception is the
promotion of TM binding to actin by the mutant A104V,
which we have suggested may directly influence actin bind-
ing.
All experiments in this study using TM9a36ox were done
with a synthetic peptide designed using the sequence for rat
-TM in the SWISS-PROT database (accession number
P04692). Recently, we realized that this sequence differs
from that in the original references (Ruiz-Opazo et al.,
1985; Ruiz-Opazo and Nadal-Ginard, 1987) and from our
own sequence determination of rat striated -TM DNA.
Residue 279, an f position in the TM heptad repeats, is
incorrectly listed as Lys in the SWISS-PROT database
whereas it should be Asn. We repeated selected experiments
with the correct N279-TM9a36ox. N279-TM9a36ox by it-
self is less stable than K279-TM9a36ox (7.6°C), but the
Tm values of binary complexes with AcTM1aZip or wt-Gly-
hcTnT70–170 and the ternary complex with AcTM1aZip and
Gly-hcTnT70–170 are within 1°C of those of K279-
TM9a36ox. These results show that the Asn279Lys change
does not affect binding of TM9a36ox to TnT and the N-
terminus of TM.
DISCUSSION
Our studies show that FHC-causing mutations in hcTnT
between residues 92 and 110 (R92L, R92Q, R92W, R94L,
A104V, and F110I) impair TM-dependent functions of
hcTnT and identify altered TM binding as a probable cause
of disease. Mutations in TnT that affect the head-to-tail
association of TM and the ability of TM to bind tightly to
actin may be expected to negatively affect myofibrillar
assembly, the cooperativity and extent of force develop-
ment, and Ca2-dependence of contraction. Mutations out-
FIGURE 4 Effect of FHC-mutations on the temperature dependence of
the unfolding of Gly-hcTnT70–170, free (A) and in complex with TM
peptides (B and C), determined by CD. Ellipticity was measured as a
function of temperature in 10 mM potassium phosphate, pH 6.5, at a
peptide concentration of 17.5 M. (A) Thermal transitions of the TM
peptides, AcTM1aZip (E), TM9a36ox (), and the TnT fragments, wt-
(‚), F110I- (ƒ), and A104V-Gly-hcTnT70–170 (); (B) Sum (  ) and
equimolar mixture of the TM overlap complex, AcTM1aZip with
TM9a36ox (E) and sum (  ) and equimolar mixture of the ternary
complex of wt-Gly-hcTnT70–170 with AcTM1aZip and TM9a36ox (‚); (C)
Sum (  ) and equimolar mixture of F110I-Gly-hcTnT70–170 with
AcTM1aZip and TM9a36ox (ƒ). The symbols in this figure represent
every 15th data point.
FIGURE 5 Correlation between the Tm of unfolding of Gly-hcTnT70–170
and function of wt- and FHC-mutants. E, TM binding as measured by the
NaCl required for elution from TM-Sepharose (Table 2); , the ability to
promote TM binding to F-actin (Table 2); Œ, the stabilization of the
Gly-hcTnT70–170-TM overlap complex (Table 3). Symbols for wild-type
(Tm  33.5°C) are slightly larger.
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side this region (I79N, E160, and E163K) had no effect on
any parameter we studied and must cause disease by other
mechanisms. The use of an hcTnT fragment and TM peptide
models has allowed investigation of specific TnT-TM in-
teractions and functions, giving new insights into the struc-
tural requirements for TnT activity.
The hcTnT70–170 fragment used in our investigation is a
highly conserved region of TnT, long known to bind to TM
and to be highly -helical (Pearlstone and Smillie, 1977;
Perry, 1998). It is no surprise, therefore, that Gly-hcTnT70–
170 is highly helical. The amino acids introduced by the
mutations are all well represented in -helices or -helical
coiled-coils (Chou and Fasman, 1974; Cohen and Parry,
1990). Although the mutations do not reduce the helical
content, some have dramatic effects on the stability in a way
that correlates with TM binding. Mutations that increase the
helical stability of Gly-hcTnT70–170 (R92L, R92W, R94L,
F110I, all with Tm values higher than physiological temper-
ature) decrease its affinity for TM and for the TM peptide
overlap model. The A104V mutation within the critical
region reduces helical stability but has no effect on TM
binding. The results suggest that one requirement for nor-
mal TM interaction is an -helix of sufficient stability, but
it cannot be too stable. An -helix that is too stable may be
too rigid to interact effectively with TM. Another possible
explanation could be that Gly-hcTnT70–170 self-associates.
To bind stoichiometrically to TM, Gly-hcTnT70–170 would
have to be monomeric. Mutations that increase the stability
of homodimers (or higher assemblies) may in turn decrease
the ability of Gly-hcTnT70–170 to interact with TM. The
R92Q mutation has little effect on stability, but it does
marginally reduce TM interaction, suggesting that addi-
tional parameters are important.
The ability of Gly-hcTnT70–170 to promote binding of
TM to actin filaments generally follows the same pattern as
TM binding: mutations between residues 92 and 110 reduce
affinity compared with wild type. We conclude from this
that TnT must bind to TM to increase TM’s affinity for
actin. Gly-hcTnT70–170 does not bind to actin alone in the
conditions of our assays, suggesting that it has its effect by
changing the ends of TM in a way that increases actin
affinity. Not all mutations follow the pattern, inferring ad-
ditional structural requirements. In particular, A104V is less
effective than wild type in promoting TM binding to actin
although the mutant binds normally to TM. Also, the E163K
mutation, outside the critical residue 92–110 region, slightly
impaired TM binding to actin.
The highly helical character of Gly-hcTnT70–170 and ear-
lier suggestions that -helical regions of TnT bind to TM,
possibly forming a triple helix (Nagano et al., 1980; Hitch-
cock et al., 1981; Ohtsuki and Nagano, 1982), led us to
develop a model incorporating the Gly-hcTnT70–170 frag-
ment into the coiled-coil TM overlap complex. Examination
of the hcTnT70–170 sequence revealed a coiled-coil heptad
repeat spanning residues 92–110, suggesting that this region
may form a coiled-coil when it binds to TM. Possible
-turns at residues 80 and 122 (Chou and Fasman, 1979)
flanking the coiled-coil region would allow TnT to bind to
the C-terminus of TM in a parallel orientation (versus
anti-parallel if there are no turns; see Fig. 1).
Fig. 6 shows a model of residues 92–110 of hcTnT
binding to the TM overlap complex. The model was con-
structed starting from the four-helix bundle overlap com-
plex proposed by McLachlan and Stewart (1975) that opti-
mizes interchain interactions in the heptad repeat known to
be important for coiled-coil stability: hydrophobic interac-
tions between interface residues a-d, a-a, and d-d; ionic
interactions, e-g; and packing of a against g and d against e
at the interface. It is well accepted that striated muscle TMs
overlap at the ends by eight to nine amino acids (Cohen et
al., 1972; McLachlan and Stewart, 1975; Phillips et al.,
1979), although the structure of the ends remains unresolved
in crystals of TM (Whitby and Phillips, 2000).
The coiled-coil region of hcTnT (residues 92–110) was
incorporated into the model by evaluating optimal inter-
chain charge-charge and hydrophobic interactions between
the C-terminal 25 amino acids of TM9a36 (encoded by
striated muscle-specific exon 9a) and TnT because Gly-
hcTnT70–170 binds more strongly to the C-terminus of TM
than to its N-terminus (see Results). In the model, the
binding region of hcTnT92–110 extends into the TM overlap
region. Heptad positions a and d are symmetric in the model
but positions e and g are not. Fig. 6 A shows the optimal
alignments in both parallel and anti-parallel orientations of
TnT. We favor the model of TnT oriented in parallel with
TM (shown in Fig. 6 B) for the following reasons. There are
more interactions favoring formation of a helix bundle:
more than 15 in parallel versus 12 and 1 destabilizing
interaction in the anti-parallel orientation (see legend to Fig.
6). The coiled-coil domain of TnT spans residues 263–281
of TM, the region of TM encoded by exon 9a that is
required for TnT binding (Hammell and Hitchcock-DeGre-
gori, 1996, 1997). Support for the parallel model also comes
from NMR studies showing that the pKa of His-79 in
skeletal TnT (corresponding to His-109 in hcTnT) is in-
creased when skTnT71–151 binds to an N-terminal TM-
peptide (Brisson et al., 1986). Although one would not
normally expect a His in a d position of a coiled-coil, it
could form a charge-charge interaction with Asp-280 in a g
position in our model. Finally, the parallel model gives us
the greatest insight into the effects of the FHC mutations
that have the most severe effect on Gly-hcTnT70–170 func-
tion. In the model, Arg-92 can form a hydrogen bond with
Gln-263. The three R92 mutations would disrupt this inter-
action. The R92L and R92W, though stabilizing the helix,
would alter the side-chain packing at the hydrophobic in-
terface so as to weaken complex formation. In the parallel
model, F110 extends into the overlap complex, potentially
binding to hydrophobic residues at the extreme N-terminus,
such as the acetylated Met-1 or Ile-4. The F110I mutation,
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the most severe mutation, would alter the packing. In both
models, A104V is in an f position in the heptad repeat,
explaining how it may influence actin binding of TM with-
out impairing TM-TnT interaction.
Our results agree with previously published work on
FHC-TnTs (full-length protein), where it is possible to
compare the data. I79N-TnT and E160-TnT have normal
TM binding and promotion of binding of TM to actin (Lin
et al., 1996; Tobacman et al., 1999; Homsher et al., 2000);
F110I-TnT was impaired in its ability to promote TM bind-
ing to actin (Tobacman et al., 1999). A possible exception is
the R92Q mutation, which in the full-length protein had no
effect on TM binding to actin, whereas in the Gly-hcTnT70–
170 peptide it had small but probably real effects on func-
tion. Transgenic mice carrying the R92Q mutation showed
myocyte disarray and dysfunctional hearts (Oberst et al.,
1998).
Physiological studies measuring Ca2 dependence of ac-
tivity, force production, shortening velocity of the I79N,
R92Q, and F110I mutations have been extensive. Systems
FIGURE 6 Coiled-coil model for the TnT-TM overlap complex. Possible parallel and anti-parallel coiled-coil interaction of hcTnT92–110 with residues
1–9 of the N-terminus of TM and the C-terminus of TM (residues 258–284 encoded by exon 9a). Favorable interactions between the N-and C-termini of
TM (marked in blue) cause TM to overlap by 8–9 amino acids as proposed by McLachlan and Stewart (1975). The hcTnT92–110 was docked to the
sequence encoded by exon 9a to satisfy favorable interactions (marked in red). Positions within a heptad repeat are given in lowercase letters. To keep the
figure simple, not all possible interactions are shown. (A) Linear open representation of the parallel (top) and anti-parallel (bottom) model; (B) Five-wheel
helical representation of the parallel interaction. FHC mutation sites are marked bold.
FHC and Mutations on a TnT Fragment 2835
Biophysical Journal 81(5) 2827–2837
employed range from in vitro motility assays and acto-
myosin S1 ATPases (Lin et al., 1996; Tobacman et al.,
1999; Homsher et al., 2000) to reconstituted myofibrils and
myofibers (Morimoto et al., 1998; Yanaga et al., 1999;
Harada et al., 2000; Szczesna et al., 2000) to adenovirus-
transfected myocytes (Marian et al., 1997; Sweeney et al.,
1998; Rust et al., 1999) and transgenic mice (Oberst et al.,
1998; Tardiff et al., 1999; Lim et al., 2000; Knollmann et
al., 2001; Miller et al., 2001). Unfortunately, the systems are
complex and varied and have often produced conflicting
results (reviewed in Hernandez et al., 2001). For this reason,
we have not attempted to relate our findings to those of the
FHC mutations in the physiological studies.
This research was supported by National Institutes of Health grant GM-
36326 to S.E.H.-D. and N.J.G.
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